Last checked at 
| AGM, EGM Calendar |
| Thursday, May 19 |
| Next |
| Merlin Entertainments |
| Informa |
| Balfour Beatty |
| Prudential |
| StatPro Group |
| Computacenter |
| PPHE Hotel Group |
| ProPhotonix |
| Sherborne Investors |
| Cineworld Group |
| Learning Technologies |
| Revolymer |
| Crossrider |
| Science Group |
| Safestyle UK |
| GLI Finance |
| Staffline Group |
| Riverstone Energy |
| Gamma Communications |
| Glencore |
| Petrofac |
| HaloSource (re recreational water business sale) |
| Ferrexpo |
| North Midland Construction |
| Portmeiron Group |
| Concurrent Technology |
| Game Digital (re loan facility with Lajedosa Investments) |
| Conviviality (re acquisition of Bibendum PLB & proposed placing) |
| Exova Group |
| LMS Capital |
| PV Crystalox Solar |
| Hiscox |
| Friday, May 20 |
| Spectris |
| Moss Bros Group |
| Applegreen |
| Richland Resources |
| Snacktime |
| Hydrogen Group |
| John Menzies |
| Hochschild Mining |
| Vislink |
| Headlam Group |
| Baillie Gifford Shin Nippon |
| Spectris |
| Monday, May 23 |
| Restore |
| Stock Spirits Group |
| Noricum Gold |
| Nasstar |
| 4D Pharma |
| Hvivo |
| Plant Healthcare |
| Synety Group |
| Vertu Capital |
| Tuesday, May 24 |
| Marshall Motor Holdings |
| Royal Dutch Shell |
| Metro Bank |
| Card Factory |
| Ranger Direct Lending Fund |
| Accesso Technology Group |
| Epwin Group |
| Belgravium Technologies |
| GVC Holdings |
| Merchants Trust |
| Keller Group |
| Telit Communications |
| Quarto Group |
| Wednesday, May 25 |
| Travis Perkins |
| e-Therapeutics |
| Electric Word |
| Igas Energy |
| Immupharma |
| Lidco Group |
| Paysafe Group |
| Dunedin Income Growth Investment Trust |
| F & C Private Equity |
| Hilton Food Group |
| Intertek Group |
| Judges Scientific |
| Mercantile Investment Trust |
| NAHL Group |
| Highland Gold Mining |
| Polypipe Group |
| SQS Software Quality |
| Alliance Pharma |
| Hastings Group Holdings |
| Copyright 2016 Alliance News Limited. All Rights Reserved. |
4 Nov 2015 10:44
ImmuPharma's Lupuzor trial on track for 2017 completion
(ShareCast News) - ImmuPharma has reached a number of important milestones in the phase three clinical trial of Lupuzor. The AIM listed company provided an update to the market on Wednesday about the drug trial, its lead programme for the potential breakthrough compound for life threatening auto imm
Read more